Patritumab deruxtecan

Drug Overview

Patritumab deruxtecan is a highly advanced, experimental cancer medicine. It belongs to a special class of treatments known as an Antibody-Drug Conjugate (ADC), which is a type of Targeted Therapy or “Smart Drug.” Unlike traditional chemotherapy that travels blindly through the body and harms healthy cells, this medication is designed to seek out specific cancer cells and deliver a powerful cancer-killing dose directly inside them. Because it is currently under review by health authorities, it is not yet available at standard pharmacies.

• Generic Name: Patritumab deruxtecan (also known in research as HER3-DXd)
• US Brand Names: None currently (Experimental drug)
• Drug Class: HER3-directed Antibody-Drug Conjugate (Targeted Therapy)
• Route of Administration: Intravenous (IV) Infusion (Given through a vein)
• FDA Approval Status: Not FDA Approved. (In mid-2024, the FDA delayed its approval due to inspection issues at a third-party manufacturing factory, not because of problems with the drug’s safety or how well it works. It is actively being researched in clinical trials.)

What Is It and How Does It Work? (Mechanism of Action)

Patritumab deruxtecan is a Targeted Therapy that works like a microscopic guided missile. To understand how it works at the molecular level, it helps to look at the three distinct parts that make up this “Smart Drug.”

1. The Guidance System (The Antibody): The first part is a lab-made protein called an antibody (patritumab). Its job is to search the body for a specific “antenna” found on the surface of many lung and breast cancer cells. This antenna is called the HER3 receptor.
2. The Connector (The Linker): Once the antibody finds the HER3 antenna, it attaches to it. The drug then gets swallowed whole by the cancer cell. Inside the cell, special enzymes break a chemical chain (the linker) that holds the drug together.
3. The Payload (The Chemotherapy): When the chain breaks, it releases a powerful chemotherapy drug called deruxtecan directly inside the cancer cell. Deruxtecan targets an enzyme called Topoisomerase I, which the cell needs to copy its DNA.

By destroying the DNA, the cancer cell can no longer grow and safely self-destructs (a process called apoptosis). Additionally, patritumab deruxtecan has a special “bystander effect.” This means the chemotherapy payload can slip out of the dying cancer cell and destroy other cancer cells hiding right next to it, even if they do not have the HER3 antennas.

FDA Approved Clinical Indications

Because patritumab deruxtecan is still an investigational medicine awaiting final regulatory decisions, it does not currently have full approval from the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Oncological Uses (Investigational Only):

• Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation, specifically for patients who have already been treated with other targeted drugs and chemotherapy.
• Advanced Breast Cancer (currently being studied in clinical trials).

Non-oncological Uses:

• None.

Dosage and Administration Protocols

Because the drug is primarily used in clinical trials (such as the HERTHENA-Lung01 study), the dosing guidelines below reflect the standard protocols used by cancer researchers.

Clinical Efficacy and Research Results

Recent clinical trial data (published between 2023 and 2024) has shown exactly how well patritumab deruxtecan works, especially for lung cancer patients who have run out of other treatment options.

• Tumor Shrinkage: In the major Phase 2 HERTHENA-Lung01 trial, researchers tested the drug on patients with EGFR-mutated lung cancer who had already tried several other heavy treatments. About 30% of these patients saw their tumors shrink significantly (Objective Response Rate).
• Controlling the Disease: The drug was able to stop the cancer from growing for an average of 5.5 months (median Progression-Free Survival).
• Overall Survival: For these heavily pre-treated patients, the average overall survival time was 11.9 months. This is considered a meaningful step forward, as these cancers are highly resistant to standard therapies.
• Brain Metastases: The trial also showed that the drug can effectively shrink tumors that have spread to the brain, which is a common and dangerous complication of lung cancer.

Safety Profile and Side Effects

Like all strong cancer treatments, patritumab deruxtecan causes side effects. Because it carries a powerful chemotherapy payload, it can affect healthy fast-growing cells, such as those in the blood, stomach, and hair.

Black Box Warning:

While not officially approved yet, drugs using the “deruxtecan” payload carry strict warnings for severe lung inflammation (Interstitial Lung Disease) and harm to unborn babies.

Common Side Effects (Occurs in >10% of patients)

• Hair thinning or complete hair loss (Alopecia)
• Upset stomach (Nausea) and throwing up
• Feeling extremely tired or weak (Fatigue)
• Decreased appetite
• Low white blood cell counts (Neutropenia), which increases the risk of catching infections
• Low blood platelet counts (Thrombocytopenia), which can cause easy bruising or bleeding

Serious Adverse Events

• Interstitial Lung Disease (ILD) / Pneumonitis: This is a severe, non-infectious inflammation and scarring of the lungs. It causes sudden trouble breathing, a new cough, or fever. If not caught early, ILD can be life-threatening.
• Severe Bone Marrow Suppression: Dangerously low levels of blood cells that can lead to severe infections or uncontrolled bleeding.

Management Strategies

• For Lung Safety: Doctors will perform regular chest CT scans. If a patient develops a cough or shortness of breath, the drug is stopped immediately, and the patient is given strong steroids to heal the lungs.
• For Nausea: The healthcare team will give strong anti-nausea medicines through the IV before the drug is administered, as well as pills to take at home.
• For Low Blood Counts: Routine blood tests are required before every single dose. If counts are too low, the doctor will delay the treatment for a week or lower the dose.

Research Areas

While there is no direct connection to stem cell therapies, patritumab deruxtecan is at the forefront of researching “acquired resistance” in oncology. When patients take targeted pills for lung cancer, the cancer cells eventually mutate to protect themselves, often by building more HER3 antennas. By using patritumab deruxtecan, scientists are proving they can use the tumor’s own escape plan against it. This concept of outsmarting the tumor’s evolving genetics is a major focus in modern medicine, opening the door to combining Antibody-Drug Conjugates (ADCs) with modern immunotherapies to achieve deeper, longer-lasting tumor destruction.

Patient Management and Practical Recommendations

Patient safety requires strict teamwork between the patient and the cancer care team. Below are the standard guidelines used when giving this medication.

Pre-treatment Tests to be Performed

• Lung Imaging: A baseline high-resolution CT scan of the chest to make sure there is no hidden lung inflammation before starting.
• Comprehensive Blood Panel: Tests to check the liver, kidneys, and ensure bone marrow is producing enough healthy blood cells.
• Pregnancy Test: For women of childbearing age, as the drug can severely harm an unborn baby.

Precautions During Treatment

• Monitor Breathing: Because of the risk of lung inflammation (ILD), patients must pay very close attention to how they are breathing every day.
• Infection Control: Since the drug lowers white blood cells, patients must take extra care to avoid crowds, sick people, and undercooked foods.

“Do’s and Don’ts” List

• DO contact your cancer team immediately if you develop a new cough, fever, or feel short of breath, even if it feels mild.
• DO drink plenty of water and eat small, frequent meals to help your stomach handle the nausea.
• DO use a highly effective method of birth control during treatment and for several months after the final dose.
• DON’T ignore a fever of 100.4°F (38°C) or higher. Treat it as a medical emergency.
• DON’T start any new vitamins, herbal supplements, or over-the-counter medicines without getting permission from your oncologist first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Patritumab deruxtecan (HER3-DXd) is an investigational drug and is not currently approved by the FDA, EMA, or other global regulatory bodies for commercial use outside of clinical trials or expanded access programs. Always consult with your oncologist or a qualified healthcare provider regarding your specific medical condition, clinical trial eligibility, and available, approved treatment options.